Pfizer's new crown vaccine stimulates a strong immune response in adolescents and has a preventive effect of 100%

Today, Pfizer and BioNTech jointly announced that the new crown vaccine BNT162b2 jointly developed by the two parties has shown 100% efficacy and a strong antibody immune response in a phase 3 clinical trial conducted in adolescents aged 12-15.

BNT162b2 is a new coronavirus vaccine based on mRNA technology.

In this phase 3 clinical trial involving 2260 adolescents aged 12-15 years, 18 COVID-19 patients with symptoms were found in the placebo group (n=1129), but none in the vaccine group (n=1131) Symptoms of COVID-19 patients.

At the same time, BNT162b2 is well tolerated in this adolescent population, and the side effects are comparable to those previously observed in 16-25 year olds.

The two companies also announced that the Phase 1/2/3 seamless clinical study in children from 6 months to 11 years of age had been launched last week.

Note: The original text has been deleted

Reference materials:

[1] PFIZER-BIONTECH ANNOUNCE POSITIVE TOPLINE RESULTS OF PIVOTAL COVID-19 VACCINE STUDY IN ADOLESCENTS.